[go: up one dir, main page]

BR0210875A - Group b streptococcus antigens and corresponding DNA fragments - Google Patents

Group b streptococcus antigens and corresponding DNA fragments

Info

Publication number
BR0210875A
BR0210875A BR0210875-5A BR0210875A BR0210875A BR 0210875 A BR0210875 A BR 0210875A BR 0210875 A BR0210875 A BR 0210875A BR 0210875 A BR0210875 A BR 0210875A
Authority
BR
Brazil
Prior art keywords
group
dna fragments
corresponding dna
antigens
streptococcus
Prior art date
Application number
BR0210875-5A
Other languages
Portuguese (pt)
Inventor
Denis Martin
Stephane Rioux
Bernard R Brodeur
Josee Hamel
Martine Boyer
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Publication of BR0210875A publication Critical patent/BR0210875A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"ANTìGENOS DE STREPTOCOCCUS DO GRUPO B E FRAGMENTOS DE DNA CORRESPONDENTES". A presente invenção se refere a antígenos, de modo mais específico antígenos do Streptococcus do Grupo B (GBS) (S.agalactiae) que podem ser úteis para a prevenção, diagnóstico e/ou para o tratamento de infecções por streptococcus."GROUP B STREPTOCOCCUS ANTIGENS AND CORRESPONDING DNA FRAGMENTS". The present invention relates to antigens, more specifically Group B Streptococcus (GBS) antigens (S.agalactiae) which may be useful for the prevention, diagnosis and / or treatment of streptococcus infections.

BR0210875-5A 2001-07-06 2002-07-05 Group b streptococcus antigens and corresponding DNA fragments BR0210875A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30310101P 2001-07-06 2001-07-06
PCT/CA2002/001019 WO2003004650A2 (en) 2001-07-06 2002-07-05 Group b streptococcus antigens and corresponding dna fragments

Publications (1)

Publication Number Publication Date
BR0210875A true BR0210875A (en) 2004-06-22

Family

ID=23170538

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210875-5A BR0210875A (en) 2001-07-06 2002-07-05 Group b streptococcus antigens and corresponding DNA fragments

Country Status (10)

Country Link
US (2) US7393536B2 (en)
EP (1) EP1407023B1 (en)
JP (2) JP4374245B2 (en)
AT (1) ATE452191T1 (en)
AU (1) AU2002317107B2 (en)
BR (1) BR0210875A (en)
CA (1) CA2453062C (en)
DE (1) DE60234772D1 (en)
ES (1) ES2337773T3 (en)
WO (1) WO2003004650A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1671981A3 (en) * 2000-10-27 2006-07-05 Chiron SRL. Nucleic acids and proteins from streptococcus group A
EP1343895B1 (en) * 2000-12-21 2008-06-18 ID Biomedical Corporation Streptococcus pyogenes antigens and corresponding dna fragments
EP1465659A4 (en) * 2001-12-21 2005-09-14 Children S Hospital And Region USE OF NEW STREPTOCOCCUS GROUP C CELL SURFACE PROTEIN PROTEASE
US8877909B2 (en) 2011-04-04 2014-11-04 Intelligent Medical Devices, Inc. Optimized oligonucleotides and methods of using same for the detection, isolation, amplification, quantitation, monitoring, screening, and sequencing of group B Streptococcus
KR101675382B1 (en) 2015-04-07 2016-11-14 (주) 씨에스코리아 Loess board manufacturing method and loess board manufactured by the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331437T2 (en) 1992-09-16 2002-09-05 The University Of Tennessee Research Corp., Knoxville ANTIGENS OF THE HYBRID M-PROTEIN AND CARRIERS FOR GROUP A STREPTOCOCCIC VACCINE
WO1999013084A1 (en) 1997-09-12 1999-03-18 Id Vaccine Group a streptococcal vaccines
TR200200633T2 (en) 1998-12-23 2002-06-21 Shire Biochem Inc. New streptococcus antigens
GB9921125D0 (en) 1999-09-07 1999-11-10 Microbial Technics Limited Proteins
EP1671981A3 (en) 2000-10-27 2006-07-05 Chiron SRL. Nucleic acids and proteins from streptococcus group A
FR2824074A1 (en) 2001-04-26 2002-10-31 Pasteur Institut SEQUENCE OF THE GENOME STREPTOCOCCUS AGALACTIAE, APPLICATION TO THE DEVELOPMENT OF VACCINES, DIAGNOSIS TOOLS, AND THE IDENTIFICATION OF THERAPEUTIC TARGETS
EP1456231A2 (en) 2001-12-20 2004-09-15 Shire Biochem Inc. Streptococcus antigens

Also Published As

Publication number Publication date
DE60234772D1 (en) 2010-01-28
US20040242844A1 (en) 2004-12-02
ATE452191T1 (en) 2010-01-15
US20090042794A1 (en) 2009-02-12
JP2005501534A (en) 2005-01-20
JP2009240316A (en) 2009-10-22
CA2453062C (en) 2013-04-02
EP1407023A2 (en) 2004-04-14
WO2003004650A3 (en) 2003-05-30
CA2453062A1 (en) 2003-01-16
EP1407023B1 (en) 2009-12-16
ES2337773T3 (en) 2010-04-29
US7393536B2 (en) 2008-07-01
JP4374245B2 (en) 2009-12-02
WO2003004650A2 (en) 2003-01-16
US7740870B2 (en) 2010-06-22
AU2002317107B2 (en) 2008-06-12
JP5194199B2 (en) 2013-05-08

Similar Documents

Publication Publication Date Title
WO2003054007A3 (en) Streptococcus antigens
BR0116370A (en) Compound, pharmaceutical composition, use of a compound, and method of treating an hppar-mediated disease or condition in a patient.
BR0213540A (en) Compounds, method for treating a patient's illness or disorder and a pharmaceutical composition comprising them
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
DE60210456D1 (en) SOLUBIZATION OF CAPSULES POLYSACCHARIDEN
DK1385864T3 (en) Anti-VEGF-2 antibodies
BR0208142A (en) Combinations comprising an antidiarrheal agent and epothilone or epothilone derivative
BR9814923A (en) Method for treating alzheimer's disease
DE60045721D1 (en) Streptococcus pneumoniae proteins and vaccines
BRPI0408085A (en) composition and method for the treatment and prevention of bacterial enteric infections
WO2003007803A3 (en) Methods for diagnosing and treating alzheimer's disease and parkinson's disease
WO2006065553A3 (en) Glycoconjugate vaccines containing peptidoglycan
PT932613E (en) EXPRESSION OF BLOCKING VIRULENCE FACTS IN S. AUREUS
WO2000058475A3 (en) Streptococcus pneumoniae antigens
BR0201524A (en) Combination Treatment for Anxiety and Depression
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
HUP0400840A2 (en) Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group a and group c streptococci
BR0109164A (en) Monoclonal antibodies to the human LDL receptor, production and use thereof
BR0210875A (en) Group b streptococcus antigens and corresponding DNA fragments
UA107177C2 (en) Immunogenic composition of CVC2 and the method of preparation of such composition
BR0201889A (en) Non-anaphylactogenic IgE Vaccines
BR0207447A (en) Corresponding polypeptides and DNA fragments of streptococcus pyogenes useful as vaccine components
DE60336063D1 (en) PROCESS, COMPOSITION AND KIT FOR THE ANTIGEN BINDING OF NORWALK-SIMILAR VIRUSES
ATE420852T1 (en) METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING BACTERIAL INFECTIONS
BR9808873A (en) Method for treating papillomavirus infection

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: SHIRE BIOCHEM INC. (CA)

Free format text: ALTERADA A SEDE DO TITULAR CONFORME REQUERIDA ATRAVES DA PETICAO NO 020050112623/RJ DE 11/10/2005.

B25A Requested transfer of rights approved

Owner name: ID BIOMEDICAL CORPORATION (CA)

Free format text: TRANSFERIDO DE: SHIRE BIOCHEM INC.

B25G Requested change of headquarter approved

Owner name: ID BIOMEDICAL CORPORATION (CA)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070097786/RJ DE 17/07/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ID BIOMEDICAL CORPORATION OF QUEBEC (CA)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time